State Street Corp Acquires 29,897 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

State Street Corp increased its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 63.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,671 shares of the company's stock after acquiring an additional 29,897 shares during the quarter. State Street Corp owned about 0.15% of Immunocore worth $2,387,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Exchange Traded Concepts LLC lifted its position in shares of Immunocore by 40.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after acquiring an additional 1,461 shares during the period. Connective Portfolio Management LLC acquired a new position in shares of Immunocore in the third quarter valued at $218,000. China Universal Asset Management Co. Ltd. lifted its position in Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after purchasing an additional 3,053 shares during the period. XTX Topco Ltd acquired a new stake in Immunocore during the second quarter worth $303,000. Finally, GSA Capital Partners LLP bought a new stake in Immunocore in the 3rd quarter valued at $406,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Trading Up 1.6 %

NASDAQ:IMCR traded up $0.47 during trading hours on Wednesday, hitting $29.50. 96,405 shares of the stock were exchanged, compared to its average volume of 493,549. The company's 50 day moving average is $31.50 and its two-hundred day moving average is $34.07. The company has a market capitalization of $1.48 billion, a P/E ratio of -31.05 and a beta of 0.73. Immunocore Holdings plc has a twelve month low of $27.69 and a twelve month high of $76.98. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. On average, sell-side analysts anticipate that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IMCR. Needham & Company LLC dropped their price objective on shares of Immunocore from $78.00 to $71.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. HC Wainwright restated a "buy" rating and set a $100.00 price target on shares of Immunocore in a research note on Thursday, October 24th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a report on Monday, September 9th. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 target price (down from $74.00) on shares of Immunocore in a report on Friday, December 13th. Finally, Mizuho lowered Immunocore from an "outperform" rating to a "neutral" rating and decreased their price target for the company from $72.00 to $38.00 in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $65.64.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.